Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amgen Inc (AMGN)

Amgen Inc (AMGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Amgen Inc ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 USA

www.amgen.com Employees: 28,000 P: 805-447-1000

Sector:

Medical

Description:

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.

Key Statistics

Overview:

Market Capitalization, $K 177,639,520
Enterprise Value, $K 225,765,520
Shares Outstanding, K 538,481
Annual Sales, $ 33,424 M
Annual Net Income, $ 4,090 M
Last Quarter Sales, $ 9,557 M
Last Quarter Net Income, $ 3,216 M
EBIT, $ 8,671 M
EBITDA, $ 14,263 M
60-Month Beta 0.45
% of Insider Shareholders 0.76%
% of Institutional Shareholders 76.50%
Float, K 534,389
% Float 99.24%
Short Volume Ratio 0.63

Growth:

1-Year Return 18.57%
3-Year Return 18.39%
5-Year Return 45.07%
5-Year Revenue Growth 43.07%
5-Year Earnings Growth 33.87%
5-Year Dividend Growth 55.17%

Per-Share Information:

Most Recent Earnings 5.64 on 11/04/25
Next Earnings Date N/A
Earnings Per Share ttm 21.87
EPS Growth vs. Prev Qtr -6.31%
EPS Growth vs. Prev Year 1.08%
Annual Dividend & Yield 9.52 (2.89%)
Annual Dividend & Yield (Fwd) 9.52 (2.80%)
Most Recent Dividend 2.380 on 11/21/25
Next Ex-Dividends Date 11/21/25
Dividend Payable Date 12/12/25
Dividend Payout Ratio 42.65%
Most Recent Split 2-1 on 11/22/99

AMGN Ratios

Ratio
Price/Earnings ttm 15.55
Price/Earnings forward 15.99
Price/Earnings to Growth 3.07
Return-on-Equity % 162.59%
Return-on-Assets % 13.18%
Profit Margin % 12.24%
Debt/Equity 5.67
Price/Sales 5.48
Price/Cash Flow 11.20
Price/Book 19.04
Book Value/Share 17.86
Interest Coverage 2.46

AMGN Dividends

Date Value
11/21/25 $2.3800
08/22/25 $2.3800
05/16/25 $2.3800
02/14/25 $2.3800
11/18/24 $2.2500
08/16/24 $2.2500
05/16/24 $2.2500
02/15/24 $2.2500
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar